Research findings bring order to the genomic chaos of ovarian high grade serous carcinoma
Can't see this email? View it online
   
  Ovarian Cancer  
  The latest ovarian cancer news from News Medical  
 New understanding of chemotherapeutic resistance in recurring ovarian cancerNew understanding of chemotherapeutic resistance in recurring ovarian cancer
 
A new editorial paper was published in Oncoscience (Volume 10) on May 11, 2023, entitled, "UPR-induced ovarian cancer cell fusion: a mechanism favoring drug resistance?"
 
 
 Research findings bring order to the genomic chaos of ovarian high grade serous carcinomaResearch findings bring order to the genomic chaos of ovarian high grade serous carcinoma
 
New research findings based on the evolution of malignant tumors increase our understanding of the characteristics of an ovarian cancer subtype that is difficult to treat.
 
 Chain reaction: Nutritional keys to a healthier diet may lie in unraveling starch structures
 
Chain reaction: Nutritional keys to a healthier diet may lie in unraveling starch structuresThe chain length distribution (CLD) of starch plays a crucial role in human health, affecting the digestibility of starch-containing foods and correlating with diseases like diabetes, cardiovascular disease, and obesity. By understanding and manipulating CLDs, it is possible to develop plant varieties that provide improved health properties in starch-based foods.
 
 
 Predicting the sensitivity of platinum-based chemotherapy for ovarian cancer patients
 
Predicting the sensitivity of platinum-based chemotherapy for ovarian cancer patientsThis article talks about a prospective cohort study that indicated HRD testing could accurately predict the sensitivity of platinum-based chemotherapy for ovarian cancer patients.
 
 
 Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer
 
Study shows efficacy and safety of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancerUpdated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d'Hebron Institute of Oncology's (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), 2-6 June in Chicago, USA.